Rapt stock skyrocketed Monday after the biotech company said its experimental hives treatment topped Roche'sRHHBY Xolair in a head-to-head 16-week study. Rapt TherapeuticsRAPT tested two doses of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback